Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. (30th April 2018)

• Record Type: Journal Article
• Authors: Safaeian, Mahboobeh; Castellsagué, Xavier; Hildesheim, Allan; Wacholder, Sholom; Schiffman, Mark H; Bozonnat, Marie-Cécile; Baril, Laurence; Rosillon, Dominique
• Is Part Of: Journal of infectious diseases. Volume 218:Number 1(2018)
• Page Start: 84
• Page End: 94
• Publication Date: 2018-04-30
• Subjects: human papillomavirus -- HPV -- immunity -- naturally acquired antibodies; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiy112
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract : Using data from PATRICIA and Costa Rica Vaccine trials, the risk of detecting a new HPV-18 infection and associated lesions was compared between women HPV seropositive and seronegative at enrollment. High HPV-18 naturally acquired antibodies were associated with partial protection. Abstract: Background: Studies on the role of antibodies produced after infection with human papillomavirus 18 (HPV-18) and subsequent protection from HPV-18 infection have been conflicting, mainly due to inadequate sample size. Methods: We pooled data from the control arms of the Costa Rica Vaccine Trial and the PATRICIA trial. Using Poisson regression we compared the risk of newly detected 1-time HPV-18 infection, HPV-18 1-year persistent infection (12MPI), and HPV-18–associated atypical squamous cells of undetermined significance or greater (ASC-US+) lesions between HPV-18 seropositive and seronegative women. Results: High HPV-18 antibodies at enrollment was associated with reduced subsequent HPV-18 detection ( P trend = 0.001; relative rate [RR] = 0.69; 95% confidence interval [CI], 0.47–1.01 for the third quartile; RR = 0.63; 95% CI, 0.43–0.94 for the fourth quartile, compared to seronegative). The risk of 12MPI showed a decreasing trend with increasing antibodies ( P trend = 0.06; RR = 0.72; 95% CI, 0.29–1.77; RR = 0.42; 95% CI, 0.13–1.32 for the third and fourth quartiles, respectively). Lastly, we observed a significant decreased risk of HPV-18 ASC-US+ with increasing antibody ( P trend = 0.01; RR = 0.46; 95% CI, 0.21–0.97 for the fourth quartile). We also observed a significant decreased risk of HPV-16 infection, 12MPI, and ASC-US+ with increasing HPV-16 antibody level. Conclusions: High HPV-18 naturally acquired antibodies were associated with partial protection from future HPV-18 infections and associated lesions. Clinical Trials Registration: NCT00128661 and NCT001226810.